Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Mon, 11.11.2024
Eleving Group S.A.
Operational and Strategic Highlights
Profitability
Eleving Group closed the first nine months of 2024 with a strong financial performance, recording revenues of EUR 157.9 mln, up by nearly 17% compared to the corresponding reporting period a year ago.
The Group maintained a diversified portfolio generating a well-balanced revenue stream from all k [ … ]
Mon, 11.11.2024
Salzgitter Aktiengesellschaft
Diversification effective – Technology Business Unit heading for a record result
Rigorous implementation of liquidity and profit improvement measures
Structural adjustments at development stage – coordination with employee representatives
Non-recurrent effects impacting the earnings forecast lay the foundations for future-proof positioning
The f [ … ]
Mon, 11.11.2024
Hannover Rück SE
Hannover Re raises profit target for 2024 and expects Group net income of around EUR 2.4 billion for 2025
Group net income after three quarters increases by 30.4% to EUR 1.8 billion
Reinsurance revenue grows by 7.0% adjusted for exchange rate effects to EUR 19.7 billion
Large losses in property and casualty reinsurance within the budgeted expec [ … ]
Mon, 11.11.2024
q.beyond AG
q.beyond increases EBITDA by € 2.1 million to € 2.2 million
Q3 2024: revenues rise to € 47.0 million, free cash flow amounts to € 1.0 million
Full-year EBITDA is now budgeted to increase by significantly more than 40% to between € 8 million and € 10 million
Cologne, 11 November 2024 – q.beyond is further increasing its earnings strength despite G [ … ]
Mon, 11.11.2024
DEMIRE Deutsche Mittelstand Real Estate AG
DEMIRE: Successful conclusion of the bond extension until the end of 2027 - Stock exchange trading of the bond resumed
Implementation of the new bond terms and conditions
Repurchase and cancellation of bonds in the amount of approximately EUR 195.4 million of the aggregate outstanding principal amount so far
Outstanding total nominal amount of t [ … ]
Mon, 11.11.2024
Continental AG
Consolidated sales of €9.8 billion (Q3 2023: €10.2 billion, -4.0 percent)
Adjusted EBIT of €873 million (Q3 2023: €642 million, +36.0 percent)
Adjusted EBIT margin of 8.9 percent (Q3 2023: 6.3 percent)
Net income of €486 million (Q3 2023: €299 million, +62.8 percent)
Adjusted free cash flow of €323 million (Q3 2023: €466 million, -30.6 percent [ … ]
Mon, 11.11.2024
Hypoport SE
Group results for Q1–Q3 2024
Hypoport reports solid earnings for nine-month period despite market conditions remaining difficult
Consolidated revenue up by 24 per cent year on year in first three quarters of 2024
Gross profit advances by 11 per cent year on year to €170 million
EBIT back at almost €12 million following losses in the prior [ … ]
Mon, 11.11.2024
LEM HOLDING SA
Geneva, 11 November 2024 – LEM (SIX: LEHN), a global leader in electrical measurement for automation, e-mobility, renewable energy, power network and railroad applications, announces its results for the first half of 2024/25 (April-September):
Sales declined 29.9% to CHF 156.5 million (H1 2023/24: CHF 223.3 million); at constant exchange rates, [ … ]
Mon, 11.11.2024
Stabilus SE
CORPORATE NEWS
Stabilus SE publishes full preliminary figures for FY2024: forecast for revenue and adjusted EBIT margin fulfilled
According to preliminary figures, revenue in FY2024 grew by 7.5% to €1,305.9 million (FY2023: €1,215.3 million)
Adjusted EBIT[1] at €157.1 million, compared to €158.4 million in the previous year, correspondin [ … ]
Mon, 11.11.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA (NOV. 11, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, t [ … ]